CollPlant Biotechnologies Ltd. (NASDAQ:CLGN – Get Free Report) was the recipient of a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 3,800 shares, a growth of 533.3% from the June 30th total of 600 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 8,000 shares, the days-to-cover ratio is presently 0.5 days.
CollPlant Biotechnologies Stock Performance
CollPlant Biotechnologies stock traded down $0.14 during mid-day trading on Thursday, reaching $4.65. 6,361 shares of the company were exchanged, compared to its average volume of 8,122. CollPlant Biotechnologies has a twelve month low of $4.22 and a twelve month high of $7.88. The firm’s 50-day simple moving average is $5.27 and its two-hundred day simple moving average is $5.41. The firm has a market cap of $53.24 million, a PE ratio of -7.12 and a beta of 0.23.
CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) last posted its quarterly earnings data on Wednesday, May 29th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). CollPlant Biotechnologies had a negative return on equity of 24.74% and a negative net margin of 70.58%. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.60 million. As a group, equities research analysts anticipate that CollPlant Biotechnologies will post -1.46 EPS for the current year.
Institutional Trading of CollPlant Biotechnologies
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Thursday, May 30th.
Read Our Latest Stock Analysis on CollPlant Biotechnologies
CollPlant Biotechnologies Company Profile
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
Further Reading
- Five stocks we like better than CollPlant Biotechnologies
- Using the MarketBeat Dividend Tax Calculator
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- What does consumer price index measure?
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- CD Calculator: Certificate of Deposit Calculator
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.